Integra LifeSciences (NASDAQ:IART) Announces Q3 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its third quarter 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.550-0.590 for the period, compared to the consensus estimate of 0.560. The company issued revenue guidance of $410.0 million-$412.0 million. Integra LifeSciences also updated its FY 2026 guidance to 2.300-2.400 EPS.

Integra LifeSciences Trading Down 21.2%

NASDAQ:IART opened at $12.68 on Friday. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $20.49. The stock has a market cap of $986.12 million, a P/E ratio of -140.87, a P/E/G ratio of 0.83 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The stock has a 50-day simple moving average of $16.69 and a 200-day simple moving average of $15.15.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. The firm had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, analysts anticipate that Integra LifeSciences will post 2.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on IART. Citigroup reissued a “neutral” rating and issued a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Weiss Ratings raised shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Thursday, June 18th. Wells Fargo & Company increased their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. Finally, Wall Street Zen downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Reduce” and an average target price of $18.86.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra expects to generate strong cash flow despite the disruption, while the proposed seven-year, $600 million Senior Secured Term Loan B could improve liquidity and refinance existing obligations. Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
• Neutral Sentiment: Preliminary third-quarter adjusted EPS guidance is $0.55-$0.59, broadly in line with the $0.56 analyst consensus, suggesting the immediate-quarter impact may be manageable. Truist also upgraded the shares to a “Hold,” indicating a more balanced view rather than a bullish recommendation. Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
• Negative Sentiment: Integra reduced its 2026 revenue forecast to $1.634 billion-$1.654 billion from $1.654 billion-$1.695 billion. Full-year EPS guidance was lowered to $2.30-$2.40 from $2.40-$2.50, below the $2.46 consensus estimate. The cuts reflect production interruptions and millions of dollars in costs associated with the Cincinnati flooding. Integra LifeSciences Lowers Revenue and Earnings Outlook for 2026
• Negative Sentiment: The $600 million debt refinancing may support operations, but it also raises concerns about borrowing costs and leverage, particularly as profitability is being reduced by the flood-related disruption. The combination of lower guidance, facility uncertainty and additional secured debt explains why IART shares have decreased sharply and traded at unusually high volume. Integra Lowers FY26 Forecast Following Cincinnati Flood; Plans $600M Debt Refinance

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.